This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 202Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
2018 | miR-375 | miRNA | Human | Downregulated in Cancer | Diagnostic and Prognostic | Liver cancer v/s Normal | p < 0.01 | Tissue | 28781668 |
2019 | miR-221 | miRNA | Human | Upregulated in Cancer | Diagnostic and Prognostic | Liver cancer v/s Normal | p < 0.01 | Tissue | 28781668 |
2025 | miR-34a-5p | miRNA | Sprague- Dawley rats | Upregulated in TAA-induced hepatocarcinogenesis (with Log fold change more than 1.5 to 4.7) | Potential Diagnostic and Prognostic * | Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC | p < 0.05 | Tissue | 28596526 |
2026 | miR-455-3p | miRNA | Sprague- Dawley rats | Downregulated in TAA-induced hepatocarcinogenesis | Potential Diagnostic and Prognostic * | Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC | p < 0.05 | Tissue | 28596526 |
2028 | EMP1-008 | LncRNA | Human | Downregulated in ICC (with log fold change of more than 2) | Diagnostic and Prognostic | ICC v/s Normal; significantly downregulated in ICC with tumor metastasis | p < 0.05 | Tissue | 28401021 |
2029 | ATF3-008 | LncRNA | Human | Downregulated in ICC (with log fold change of more than 2) | Diagnostic and Prognostic | ICC v/s Normal; significantly downregulated in ICC with tumor metastasis | p < 0.05 | Tissue | 28401021 |
2030 | RCOR3-013 | LncRNA | Human | Downregulated in ICC (with log fold change of more than 2) | Diagnostic and Prognostic | ICC v/s Normal; significantly downregulated in ICC with tumor metastasis | p < 0.05 | Tissue | 28401021 |
2032 | miR-9-3 | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2033 | miR-10b | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2034 | miR-31 | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2035 | miR-519c | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2036 | miR-522 | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2037 | miR-3660 | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2038 | miR-4784 | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2039 | miR-6883 | RNAs | Human | Upregulated in the liver cancer cell lines (0.33 fold) | Prognostic | HBV-HCC v/s Normal; Can predict survival of patients | p < 0.05 | Tissue | 28322348 |
2040 | Promoter methylation of HCCS1 | RNAs | Human | NA | Diagnostic and Prognostic | HCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage | p < 0.001 | Serum | 28189396 |
2041 | AFP | Protein | Human | NA | Diagnostic and Prognostic | HCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage | p < 0.001 | Serum | 28189396 |
2042 | AFP, Promoter methylation of HCCS1 | Protein and RNA | Human | NA | Diagnostic and Prognostic | HCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage | p < 0.05 | Serum | 28189396 |
2044 | lncBRM | LncRNA | Human | Upregulated in HCC tumours and liver CSCs | Diagnostic and Prognostic | Liver CSCs (Cancer stem cells) and early and advanced HCC tumours | p < 0.001 | Tissue | 27905400 |
2053 | CFL1 | Protein | Human cell lines and Mice | Upregulated in HBV-HCC | Diagnostic and Prognostic | HBV-HCC vs normal | p < 0.05 | Tissue | 27708241 |
2054 | ADFP | Protein | Human cell lines and Mice | Upregulated in HBV-associated HCC | Diagnostic and Prognostic | HBV-HCC vs normal | p < 0.05 | Tissue | 27708241 |
2055 | TRIM32 | Protein | Human | Upregulated in HCC tumor tissues and HCC cell lines. | Diagnostic and Prognostic | HCC v/s Normal; significant predictor for the overall survival time of HCC patients and positively correlated with histological grade, tumor sizes of patients | p < 0.05 | Tissue | 27573002 |
2058 | HIF1A | Protein | Human | Upregulated in at both an mRNA and protein level in patients with PLC | Diagnostic and Prognostic | Cancer v/s Normal; predict survival of patients | p < 0.05 | Tissue | 27173353 |
2059 | VEGF | Protein | Human | Upregulated in at both an mRNA and protein level in patients with PLC | Diagnostic and Prognostic | Cancer v/s Normal; predict survival of patients | p < 0.05 | Tissue | 27173353 |
2088 | Aspartate aminotransferase to white blood cell count ratio (AWR) | Others | Human | AWR > 5.2 was an adverse predictor of DFS and OS in HCC after hepatectomy | Prognostic | HCC patients with AWR >5.2 v/s HCC patients with AWR <5.2; predict survival of patients | p < 0.01 | Blood | 27057915 |
2092 | DLC1 | RNAs | Human | Downregulated in HCC | Prognostic | Cancer v/s Normal; predict survival of patients | p < 0.05 | Tissue | 26846339 |
2102 | CPE | RNAs | Human | CPE expression level was also significantly correlated with the tumor recurrence for both stage i.e. Stage-I and Stage-II | Prognostic | Recurrence between stage-I v/s stage-II | p < 0.01 | Tissue | 26803519 |
2107 | Combination of S100A9 and GRN | Others | Human | Downregulated in HCC patients | Diagnostic and Prognostic | Normal vs HCC | p < 0.001 | Urine | 26675302 |
2109 | DHCR24 Auto-antibody | Protein | Human | Upregulated in CHC (Chronic Hepatitis C) v/s healthy | Prognostic | Normal vs Chronic heaptitis (CHV) | p < 0.0001 | Serum | 26288822 |
2110 | DHCR24 Auto-antibody | Protein | Human | DHCR24 was up-regulated in HCV-positive, but not HBV-positive tissues or HBV-negative, HCV-negative HCC | Prognostic | HCC vs Chronic heaptitis (CHV)/healthy/Liver cirrhosis | p < 0.0001 | Serum | 26288822 |
2116 | miR-128-2 | miRNA | Human | Upregulated in HCC tissues | Prognostic | HCC v/s Normal, predict survival of patients | p < 0.01 | Serum | 25642945 |
2118 | HNF4A, RelA | miRNA | Human | upregulated in hepatoma cells | Prognostic | L-HNF4α group v/s hig-HNF4α group; associated with survival of patients | p < 0.05 | Tissue | 24752868 |
2132 | CYP3A4 | Protein | Human | Upregulated in in hepatitis B virus-associated liver cirrhosis and stage I hepatocellular carcinoma, | Prognostic | HCC vs adjacent non-tumor and stageII v/s stage-III; predict early stage | p < 0.05 | Tissue and Cells | 23891548 |
2133 | miR-1 | miRNA | Human | Increasead concentration showed longer OS in HCC | Prognostic | HCC v/s Liver Cirrhosis; predict survival of patients | p < 0.01 | Serum | 23810247 |
2134 | ENO1 | Protein | Human | Upregulated in patients with precirrhotic stage of liver fibrosis than that in patients with cirrhosis/liver cancer/healthy individuals. | Prognostic | Liver fibrosis v/s cirrhosis/liver cancer/normal; predict early stage of disease | p < 0.01 | Serum | 23458688 |
2135 | XPO4 | Protein | Human | Upregulated in paracancerous than in cancerous liver tissue | Prognostic | Normal vs HCC; predict survival of patients | p < 0.0001 | Tissue | 23251252 |
2136 | TGFβ1 | Protein | Human | Upregulated in paracancerous than in cancerous liver tissue | Prognostic | Normal vs HCC; predict survival of patients | p < 0.0001 | Tissue | 23251252 |
2137 | elF5A2 | Protein | Human | Upregulated in paracancerous than in cancerous liver tissue | Prognostic | Normal vs HCC; predict survival of patients | p < 0.0001 | Tissue | 23251252 |
2138 | ANGPTL4 | Protein | Human | Upregulated in paracancerous than in cancerous liver tissue | Prognostic | Normal vs HCC; predict survival of patients | p < 0.0001 | Tissue | 23251252 |
2160 | miR-515-3p | miRNA | Human | Upregulated in HCC | Prognostic | HCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients | p < 0.01 | Tissue | 22429613 |
2161 | miR-518a-3p | miRNA | Human | Upregulated in HCC | Prognostic | HCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients | p < 0.01 | Tissue | 22429613 |
2162 | miR-520f | miRNA | Human | Upregulated in HCC | Prognostic | HCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients | p < 0.01 | Tissue | 22429613 |
2163 | miR-525-3p | miRNA | Human | Upregulated in HCC | Prognostic | HCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients | p < 0.01 | Tissue | 22429613 |
2167 | CORO1C | Protein | Human | Upregulated in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis and higher coronin-1C expression had more advanced stage in patients | Prognostic | Agressive or advanced-stage HCC v/s less-aggressive HCC; predict metastatic stage | p < 0.05 | Tissue and Cells | 20181269 |
2178 | miR-122 | miRNA | Human | variable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in | Diagnostic and Prognostic | Normal vs HCC; associated with survival, tumor size and differentiation status | p < 0.001 | Tissue and Cells | 19617899 |
2179 | lamin B1 | Protein | Human | Upregulated in liver cancer patients | Diagnostic and Prognostic | Normal vs HCC; significantly associated with the increased number of tumor nodules , the size of tumors, and tumor stage | p < 0.01 | Plasma | 19522540 |
2199 | MTHFR | RNAs | Human | MTHFR polymorphism was associated with HCC occurrence | Prognostic | Normal vs HCC; predict recurrence in patients | p < 0.05 | Tissue | 29185200 |
2207 | NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index) | Neutrophils and lyphocytes (Others) | Human | NLR and SII in patients associated with more advanced stages of HCC | Prognostic | Normal vs HCC; associated with TNM stage, PST and survival of patients | p < 0.05 | Blood | 29123264 |
2208 | SULT1A3/4 | Protein | Human | Upregulated in HCC | Prognostic | HCC v/s Normal; associated with metastatsis of patients | p < 0.01 | Tissue | 29025375 |
2219 | AFP, GGT, ALT, AST | Protein | Male Sprague-Dawley rats | Downregulated | Potential Prognostic * | HCC v/s Normal/treated with AEA; associated with progression | p < 0.0001 | Serum | 28900384 |